Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, whether his Department has made an assessment of the potential merits of establishing an observational trial for children and young people on private prescriptions for drug-resistant epilepsy who cannot access medical cannabis on the NHS.

The Department funds research on health and social care through the National Institute for Health and Care Research (NIHR). The NIHR welcomes funding applications for research into any aspect of human health and care, including medicinal cannabis for drug-resistant epilepsy. These applications are subject to peer review and judged in open competition, with awards being made on the basis of the importance of the topic to patients and health and care services, value for money, and scientific quality​​.

The NIHR and NHS England have confirmed over £9 million in funding for clinical trials to investigate whether two different cannabis-based medicines, one containing cannabidiol (CBD) and one containing a combination of CBD and tetrahydrocannabinol, are safe and effective treatments for drug-resistant epilepsies in adults and children. The trials will produce evidence of significant scientific value suitable for informing future clinical and commissioning decisions. While observational studies can be useful in some circumstances, they cannot demonstrate whether a treatment is ​safe or ​effective and would therefore be of limited scientific value compared with these trials.